Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Relapse Following Electroconvulsive Therapy for Schizophrenia: A Systematic Review and Meta-analysis

View through CrossRef
Abstract Background Evidence regarding schizophrenia relapse following acute electroconvulsive therapy (ECT) is sparse compared with that for depression, and we have no clear consensus on relapse proportions. We aimed to provide longitudinal information on schizophrenia relapse following acute ECT. Study Design This systematic review and meta-analysis included randomised controlled trials (RCTs) and observational studies on post-acute ECT relapse and rehospitalization for schizophrenia and related disorders. For the primary outcome, we calculated the post-acute ECT pooled relapse estimates at each timepoint (3, 6, 12, and 24 months post-acute ECT) using a random effects model. For subgroup analyses, we investigated post-acute ECT relapse proportions by the type of maintenance therapy. Study Results Among a total of 6413 records, 29 studies (3876 patients) met our inclusion criteria. The risk of bias was consistently low for all included RCTs (4 studies), although it ranged from low to high for observational studies (25 studies). Pooled estimates of relapse proportions among patients with schizophrenia responding to acute ECT were 24% (95% CI: 15-35), 37% (27-47), 41% (34-49), and 55% (40-69) at 3, 6, 12, and 24 months, respectively. When continuation/maintenance ECT was added to antipsychotics post-acute ECT, the 6-month relapse proportion was 20% (11-32). Conclusion Relapse occurred mostly within 6 months post-acute ECT for schizophrenia, particularly within the first 3 months. Relapse proportions plateaued after 6 months, although more than half of all patients could be expected to relapse within 2 years. Further high-quality research is needed to optimise post-acute ECT treatment strategies in patients with schizophrenia.
Title: Relapse Following Electroconvulsive Therapy for Schizophrenia: A Systematic Review and Meta-analysis
Description:
Abstract Background Evidence regarding schizophrenia relapse following acute electroconvulsive therapy (ECT) is sparse compared with that for depression, and we have no clear consensus on relapse proportions.
We aimed to provide longitudinal information on schizophrenia relapse following acute ECT.
Study Design This systematic review and meta-analysis included randomised controlled trials (RCTs) and observational studies on post-acute ECT relapse and rehospitalization for schizophrenia and related disorders.
For the primary outcome, we calculated the post-acute ECT pooled relapse estimates at each timepoint (3, 6, 12, and 24 months post-acute ECT) using a random effects model.
For subgroup analyses, we investigated post-acute ECT relapse proportions by the type of maintenance therapy.
Study Results Among a total of 6413 records, 29 studies (3876 patients) met our inclusion criteria.
The risk of bias was consistently low for all included RCTs (4 studies), although it ranged from low to high for observational studies (25 studies).
Pooled estimates of relapse proportions among patients with schizophrenia responding to acute ECT were 24% (95% CI: 15-35), 37% (27-47), 41% (34-49), and 55% (40-69) at 3, 6, 12, and 24 months, respectively.
When continuation/maintenance ECT was added to antipsychotics post-acute ECT, the 6-month relapse proportion was 20% (11-32).
Conclusion Relapse occurred mostly within 6 months post-acute ECT for schizophrenia, particularly within the first 3 months.
Relapse proportions plateaued after 6 months, although more than half of all patients could be expected to relapse within 2 years.
Further high-quality research is needed to optimise post-acute ECT treatment strategies in patients with schizophrenia.

Related Results

Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
The Role of Whole Body STIR MRI in Assessing First Biochemical Relapse in Patients with Myeloma
The Role of Whole Body STIR MRI in Assessing First Biochemical Relapse in Patients with Myeloma
Background: Myeloma remains an incurable disease and most patients will relapse. The optimal timing of salvage initiation remains uncertain although there is a trend to treating ea...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
Abstract The evolutionary model of cancer progression suggests that malignant clones survive initial therapy and acquire new mutations, ultimately resulting in thera...
Fregoli Syndrome: A Case Report and Literature Review
Fregoli Syndrome: A Case Report and Literature Review
Abstract Introduction: Fregoli syndrome is a rare misidentification disorder that can disrupt behavior, endanger safety, and impair quality of life. Its occurrence in young adults ...
Parenting style, family support, and relapse among schizophrenia patients: a literature review
Parenting style, family support, and relapse among schizophrenia patients: a literature review
Schizophrenia is a mental health problem that is quite widespread in Indonesia. Relapse among patients with Schizophrenia is related to parenting style and family support. This stu...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...

Back to Top